title: Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension.
abstract: Acute vasoreactivity testing for patients with pulmonary arterial hypertension (PAH) has been reported to be useful to identify patients with sustained beneficial response to oral calcium-channel blockers (CCBs), but there is a risk of exacerbation during the testing with oral CCBs. Therefore, we developed a testing method utilizing intravenous nicardipine, a short-acting CCB, and examined the safety and usefulness of acute vasoreactivity testing with nicardipine in PAH patients. Acute vasoreactivity testing with nicardipine was performed in 65 PAH patients. Nicardipine was administered by short-time continuous infusion (1 μg·kg⁻¹·min⁻¹ for 5 min and 2 μg·kg⁻¹·min⁻¹ for 5 min) followed by bolus injection (5 μg/kg). Hemodynamic responses were continuously measured using a right heart catheter. Acute responders were defined as patients who showed a decrease in mean pulmonary artery pressure of at least 10 mmHg to an absolute level below 40 mmHg with preserved or increased cardiac output. Two acute responders and sixty-three non-acute responders were identified. There was no hemodynamic instability requiring additional inotropic agents or death during the testing. Acute responders had good responses to long-term oral CCBs. The acute vasoreactivity testing with nicardipine might be safe and useful for identifying CCB responders in PAH patients.
authors.affiliation: Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Saito
authors.forename: Kazufumi
authors.initials: K
authors.lastname: Nakamura
authors.forename: Katsumasa
authors.initials: K
authors.lastname: Miyaji
authors.forename: Satoshi
authors.initials: S
authors.lastname: Akagi
authors.forename: Hiroki
authors.initials: H
authors.lastname: Mizoguchi
authors.forename: Aiko
authors.initials: A
authors.lastname: Ogawa
authors.forename: Soichiro
authors.initials: S
authors.lastname: Fuke
authors.forename: Hideki
authors.initials: H
authors.lastname: Fujio
authors.forename: Takahiko
authors.initials: T
authors.lastname: Kiyooka
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nagase
authors.forename: Kunihisa
authors.initials: K
authors.lastname: Kohno
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Morita
authors.forename: Kengo F
authors.initials: KF
authors.lastname: Kusano
authors.forename: Hiromi
authors.initials: H
authors.lastname: Matsubara
authors.forename: Tohru
authors.initials: T
authors.lastname: Ohe
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ito
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002302:Cardiac Output / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods*; D004351:Drug Resistance; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D009529:Nicardipine